Congestive heart failure end-of-life considerations: Difference between revisions

Jump to navigation Jump to search
(New page: {{Infobox_Disease | Name = Heart failure | Image = | Caption = | DiseasesDB = 16209 | ICD10 = {{ICD10|I|50|0|i|50}} | ICD9 = {{...)
 
No edit summary
Line 38: Line 38:


===Class III===
===Class III===
''}}
1. Aggressive procedures performed within the final days of life (including [[intubation]] and implantation of a [[cardioverter-defibrillator]] in patients with NYHA functional class IV symptoms who are not anticipated to experience clinical improvement from available treatments) are not appropriate. ''(Level of Evidence: C)''}}


==See Also==
==See Also==

Revision as of 14:06, 11 June 2009

Heart failure
ICD-10 I50.0
ICD-9 428.0
DiseasesDB 16209
MedlinePlus 000158
eMedicine med/3552 
MeSH D006333

WikiDoc Resources for Congestive heart failure end-of-life considerations

Articles

Most recent articles on Congestive heart failure end-of-life considerations

Most cited articles on Congestive heart failure end-of-life considerations

Review articles on Congestive heart failure end-of-life considerations

Articles on Congestive heart failure end-of-life considerations in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Congestive heart failure end-of-life considerations

Images of Congestive heart failure end-of-life considerations

Photos of Congestive heart failure end-of-life considerations

Podcasts & MP3s on Congestive heart failure end-of-life considerations

Videos on Congestive heart failure end-of-life considerations

Evidence Based Medicine

Cochrane Collaboration on Congestive heart failure end-of-life considerations

Bandolier on Congestive heart failure end-of-life considerations

TRIP on Congestive heart failure end-of-life considerations

Clinical Trials

Ongoing Trials on Congestive heart failure end-of-life considerations at Clinical Trials.gov

Trial results on Congestive heart failure end-of-life considerations

Clinical Trials on Congestive heart failure end-of-life considerations at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Congestive heart failure end-of-life considerations

NICE Guidance on Congestive heart failure end-of-life considerations

NHS PRODIGY Guidance

FDA on Congestive heart failure end-of-life considerations

CDC on Congestive heart failure end-of-life considerations

Books

Books on Congestive heart failure end-of-life considerations

News

Congestive heart failure end-of-life considerations in the news

Be alerted to news on Congestive heart failure end-of-life considerations

News trends on Congestive heart failure end-of-life considerations

Commentary

Blogs on Congestive heart failure end-of-life considerations

Definitions

Definitions of Congestive heart failure end-of-life considerations

Patient Resources / Community

Patient resources on Congestive heart failure end-of-life considerations

Discussion groups on Congestive heart failure end-of-life considerations

Patient Handouts on Congestive heart failure end-of-life considerations

Directions to Hospitals Treating Congestive heart failure end-of-life considerations

Risk calculators and risk factors for Congestive heart failure end-of-life considerations

Healthcare Provider Resources

Symptoms of Congestive heart failure end-of-life considerations

Causes & Risk Factors for Congestive heart failure end-of-life considerations

Diagnostic studies for Congestive heart failure end-of-life considerations

Treatment of Congestive heart failure end-of-life considerations

Continuing Medical Education (CME)

CME Programs on Congestive heart failure end-of-life considerations

International

Congestive heart failure end-of-life considerations en Espanol

Congestive heart failure end-of-life considerations en Francais

Business

Congestive heart failure end-of-life considerations in the Marketplace

Patents on Congestive heart failure end-of-life considerations

Experimental / Informatics

List of terms related to Congestive heart failure end-of-life considerations

Cardiology Network

Discuss Congestive heart failure end-of-life considerations further in the WikiDoc Cardiology Network
Adult Congenital
Biomarkers
Cardiac Rehabilitation
Congestive Heart Failure
CT Angiography
Echocardiography
Electrophysiology
Cardiology General
Genetics
Health Economics
Hypertension
Interventional Cardiology
MRI
Nuclear Cardiology
Peripheral Arterial Disease
Prevention
Public Policy
Pulmonary Embolism
Stable Angina
Valvular Heart Disease
Vascular Medicine

Template:WikiDoc Cardiology News Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview of End-Of-Life Considerations for Congestive Heart Failure Patients

ACC / AHA Guidelines- Treatment of Patients who have Concomitant Disorders (DO NOT EDIT) [1]

Class I

1. Ongoing patient and family education regarding prognosis for functional capacity and survival is recommended for patients with HF at the end of life. (Level of Evidence: C)

2. Patient and family education about options for formulating and implementing advance directives and the role of palliative and hospice care services with reevaluation for changing clinical status is recommended for patients with HF at the end of life. (Level of Evidence: C)

3. Discussion is recommended regarding the option of inactivating ICDs for patients with HF at the end of life. (Level of Evidence: C)

4. It is important to ensure continuity of medical care between inpatient and outpatient settings for patients with HF at the end of life. (Level of Evidence: C)

5. Components of hospice care that are appropriate to the relief of suffering, including opiates, are recommended and do not preclude the options for use of inotropes and intravenous diuretics for symptom palliation for patients with HF at the end of life. (Level of Evidence: C)

6. All professionals working with HF patients should examine current end-of-life processes and work toward improvement in approaches to palliation and end-of-life care. (Level of Evidence: C)

Class III

1. Aggressive procedures performed within the final days of life (including intubation and implantation of a cardioverter-defibrillator in patients with NYHA functional class IV symptoms who are not anticipated to experience clinical improvement from available treatments) are not appropriate. (Level of Evidence: C)

See Also

Sources

  • The ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult [1]

References

  1. 1.0 1.1 Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005 Sep 20; 112(12): e154-235. Epub 2005 Sep 13. PMID 16160202

Template:SIB


Template:WikiDoc Sources